Dicerna Pharmaceuticals (DRNA) PT Lowered to $22 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Dicerna™ Reports Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update
March 11, 2019 4:05 PM EDT2018 was a Milestone Year for Dicerna Across a Variety of Fronts, Including Data Readouts for Primary Hyperoxaluria, Business Development Collaborations and a Successful Follow-On Offering
Companys Robust Cash Position Provides Funds Beyond 2020 to Fuel Pipeline Advancement and Growth
Management to Host Conference Call Today at 4:30 p.m. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals,... More
